Put companies on watchlist
Destiny Pharma PLC
ISIN: GB00BDHSP575
WKN: A2DW69
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Destiny Pharma PLC · ISIN: GB00BDHSP575 · EQS - Company News (5 News)
Country: USA · Primary market: United Kingdom · EQS NID: 1492837
21 November 2022 03:19PM

Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections


EQS-News: Destiny Pharma PLC
Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections

21.11.2022 / 15:19 CET/CEST
The issuer is solely responsible for the content of this announcement.


0.jpgContact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com


News Source: News Direct


21.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Destiny Pharma PLC
United States
ISIN: GB00BDHSP575
EQS News ID: 1492837

 
End of News EQS News Service

1492837  21.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1492837&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Destiny Pharma PLC
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.